Cain McClary, MD, is the Founder and Managing Partner of KdT Ventures. See sector focus and contact routes.
Cain McClary, MD, is the Founder and Managing Partner of KdT Ventures, an early-stage frontier science venture capital firm he established in 2017 [2][3]. His investment thesis targets pre-seed through Series A companies reprogramming chemistry and biology via computational platforms, focusing on sectors like synthetic biology, computational drug discovery, and applied physics within the U.S. [2][6]. KdT typically provides the first institutional capital with check sizes ranging from $500,000 to $5 million, often acting as the lead investor [2]. Notable portfolio companies include Azitra and Checkerspot, where McClary serves as a Board Member, alongside a diversified portfolio of 51 companies [2][5]. As a physician-scientist, McClary distinguishes his approach by investing at the intersection of deep science and rigorous technology rather than incremental improvements [2][9]. He has publicly discussed his venture building philosophy in interviews, emphasizing the goal of supporting teams that architect the world at a molecular level [6][7].
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Austin when building a target list.
Investors like Cain McClary · Full investor directory · Investor access · Company funding database